Therapeutic leukapheresis with severe pertussis: evaluating efficacy, feasibility, and safety Authors: Yixin Gao, Ding Liu, Zitian Lu, Zhijiang Chen, Gang Wang, Minghui Yang, Linyan Wu, Shaowen Li, Yongzheng Peng, Guoqiang Liang Published: 2026 ABSTRACT AbstractBackgroundSevere pertussis with hyperleukocytosis (WBC ≥ 50 × 109/L) carries high mortality in infants. While exchange transfusion (ET) is a commonly recommended intervention, it is resource-intensive and non-selective. Therapeutic leukapheresis (TL) offers targeted leukoreduction but lacks robust pediatric evaluation in pertussis. We assessed TL’s efficacy, safety, and feasibility compared to ET.Study design and methodsThis retrospective analysis enrolled children aged ≤ 4 years hospitalized with severe pertussis from Jan 1st 2024 to May 31st 2024. Patients were stratified into three groups: 4 patients underwent TL alone (Primary TL), 4 patients received ET alone (ET Only), and 6 patients received both (Salvage TL) due to refractory disease. We compared clinical characteristics, hematological responses, resource utilization, and survival outcomes.ResultsPrimary TL reduced median WBC counts from 50.6 to 24.8×109/L. ET Only reduced WBC from 43.0 to 25.6×109/L. In the Salvage TL group, TL succeeded in lowering WBC counts (median reduction 56.4%) where prior ET had failed. Resource utilization differed markedly: ET required substantial blood products (median 2.75 U RBCs, 200 mL plasma), whereas Primary TL utilized a fixed 1.5 U RBC volume for circuit priming to prevent dilutional anemia, with no plasma consumption (p=0.02). Post-treatment platelet (PLT) counts were comparable between Primary TL and ET groups (p=1.000). Although two deaths (20% of total TL procedures) occurred, both were in the Salvage group (33.3% mortality). The Primary TL group had a 0% mortality rate, identical to the ET Only group.ConclusionsTL demonstrates robust leukoreduction efficiency and significant blood resource conservation compared to ET. Safety outcomes for Primary TL were equivalent to ET. Mortality was driven by refractory disease in salvage cases. TL represents a viable, blood-sparing alternative for severe pertussis.Keywords: Therapeutic Leukapheresis, Severe Pertussis, Exchange Transfusion, Hyperleukocytosis, Infants Introduction Pertussis, commonly known as whooping cough, remains a significant global public health challenge despite widespread vaccination coverage. While often manifesting as a self-limiting respiratory illness in older children and adults, the disease imposes a disproportionately severe burden on young infants, particularly those under 6 months of age who have not yet completed their primary immunization series [1]. In a subset of these vulnerable infants, the infection progresses to a critical phenotype clinically termed “malignant pertussis.” This fulminant presentation is characterized by severe pneumonia, refractory hypoxemia, and, most notably, extreme hyperleukocytosis (white blood cell [WBC] count ≥ 50 × 109/L, and occasionally exceeding 100 × 109/L) [2, 3]. The pathophysiology of mortality in malignant pertussis is inextricably linked to this rapid and uncontrolled leukocytosis. The sheer magnitude of leukocytes leads to the formation of aggregates that mechanically obstruct the pulmonary microvasculature, leading to increased pulmonary vascular resistance, severe pulmonary arterial hypertension (PAH), and subsequent right ventricular failure or cardiogenic shock [4, 5]. Clinical data indicate that hyperleukocytosis is an independent predictor of mortality, with case fatality rates surpassing 70–80% once PAH and cardiogenic shock supervene [6, 7]. Therefore, rapid cytoreduction with lowering the WBC burden is considered a cornerstone of emergency management to break the cycle of pulmonary obstruction and hemodynamic collapse. Currently, Exchange Transfusion (ET) is a commonly recommended intervention for leukoreduction in severe pertussis [8]. By replacing the infant’s blood with donor blood, ET removes circulating leukocytes, pertussis toxin, and inflammatory cytokines. However, ET is an indiscriminate procedure with significant limitations. Mechanistically, it involves the non-selective removal of blood components, meaning that the infant’s healthy red blood cells (RBCs) and platelets are discarded along with the pathological leukocytes [9]. This necessitates the use of massive volumes of donor blood products, typically double the infant’s total blood volume, which exposes the patient to risks of transfusion-related acute lung injury (TRALI), citrate toxicity, hypocalcemia, and hemodynamic instability [10]. Furthermore, the “washout” efficiency of ET diminishes exponentially as the procedure progresses, making it difficult to achieve complete leukoreduction in cases with extremely high tumor-like burdens [1]. Therapeutic Leukapheresis (TL) presents a comparative efficient alternative. Widely used in oncology for managing hyperleukocytosis in acute leukemia, TL utilizes automated blood cell separators to specifically target and remove the “buffy coat” layer containing leukocytes while returning plasma and RBCs to the patient [11, 12]. This specificity offers two major advantages: distinctively higher efficiency in reducing WBC counts and a drastic reduction in the requirement for donor blood products. Despite these advantages, TL has not been robustly evaluated in pediatric pertussis. Its application in infants is technically challenging due to the need for large-bore central venous access, the necessity of priming the extracorporeal circuit to prevent hemodilution, and the potential for fluid shifts in hemodynamically unstable babies [13]. Consequently, reports on TL in this context are largely limited to sporadic case series, and no consensus exists regarding its safety profile compared to ET. The imperative to evaluate TL has been further amplified by recent global healthcare challenges. The scarcity of blood products, exacerbated by crises such as the COVID-19 pandemic and seasonal fluctuations in blood donation, has frequently complicated the management of patients requiring massive transfusions like ET [14]. In scenarios where compatible whole blood or RBCs are unavailable, the ability of TL to achieve cytoreduction with minimal blood product support becomes a critical clinical asset. Between Jan 1st 2024 to May 31st 2024, facing both severe clinical presentations and resource constraints, our center employed TL to treat a cohort of infants with severe pertussis. This study presents a comprehensive retrospective analysis of these cases, comparing their clinical trajectories, leukoreduction efficacy, and safety outcomes against a concurrent group treated with ET. Our objective is to determine whether TL can serve as a feasible, safe, and effective alternative to ET, particularly for patients with refractory hyperleukocytosis or in settings with limited blood product availability. Methods Study design and patient population This retrospective cohort study was conducted at the Pediatric Intensive Care Unit (PICU) of Zhujiang Hospital, Southern Medical University, China. We enrolled pediatric patients aged ≤ 4 years diagnosed with severe pertussis between January and May 2024. Inclusion criteria were as follows: (1) A confirmed diagnosis of pertussis based on the Guidelines for Diagnosis, Management, and Prevention of Pertussis in China (2024 Edition) [1]; (2) Classification as “severe pertussis,” defined by the presence of recurrent apnea, refractory hypoxemia, pertussis encephalopathy, or cardiovascular dysfunction; (3) Hyperleukocytosis, defined as a peripheral blood leukocyte count ≥ 50 × 109/L, or ≥ 30 × 109/L with progressive escalation and clinical deterioration; and (4) Availability of complete clinical data with a follow-up period exceeding six months. Exclusion criteria included: Patients with unconfirmed diagnoses, incomplete medical records, or failure to obtain informed consent. The study protocol was approved by the Ethics Committee of Zhujiang Hospital, Southern Medical University (Approval No. 2025-KY-068). Written informed consent was obtained from the parents or legal guardians of all participants. Data collection and definitions Clinical and laboratory data were retrospectively extracted from electronic medical records at baseline (pre-procedure) and immediately post-procedure. The comprehensive dataset encompassed vital signs (respiratory rate, heart rate, and invasive or non-invasive blood pressure), hematological parameters (complete blood counts including WBC, neutrophil, lymphocyte, and platelet counts, as well as hemoglobin levels), metabolic markers derived from arterial blood gas analysis (such as pH and lactate levels), and detailed records of blood product consumption during procedures. Additionally, cardiac function and pulmonary artery pressure were assessed via echocardiography. Treatment efficacy was evaluated based on the magnitude of leukoreduction, alleviation of cardiorespiratory symptoms, and survival outcomes, while safety monitoring involved the continuous assessment of procedure-related adverse events, specifically febrile non-hemolytic transfusion reactions, allergic reactions, transfusion-associated circulatory overload, and catheter-related complications. Instruments and reagents Laboratory analyses were performed using a SYSMEX XN-5000 hematology analyzer (Sysmex Corporation, Japan) and an IH-1000 automated blood typing system (BIO-RAD, USA). Therapeutic procedures utilized the COM.TEC blood cell separator (Fresenius Kabi AG, Germany) with the P1YA tubing set (KIT281). Ancillary fluids included Anticoagulant Citrate Dextrose Solution A (ACD-A; Shandong Gaowei Group), 0.9% sodium chloride, and 10% calcium gluconate. Therapeutic Leukapheresis (TL) procedure Leukapheresis was performed using the Fresenius Kabi COM.TEC separator utilizing the automated mononuclear cell (MNC) collection protocol. Vascular access was secured via a central venous catheter, typically placed in the internal jugular vein. To mitigate the risk of hemodilution and anemia in these low-weight infants, the extracorporeal circuit was primed with ABO and RhD-compatible, leukocyte-reduced suspended red blood cells (approximately 1.5 units superior), cross-matched by both saline and antiglobulin tests. This priming volume was utilized to prevent dilutional anemia in these low-weight infants. ACD-A was used as the anticoagulant, with the whole blood-to-anticoagulant ratio initially set at 10:1 and titrated to 12:1 after three cycles based on patient tolerance. Procedural parameters were strictly controlled: The blood flow rate was maintained between 10 and 20 mL/min, adjusted according to the patient’s weight and hemodynamic stability. The target processing volume was set at 1.0 to 2.2 times the patient’s total blood volume (TBV) to achieve a target WBC reduction of > 40%. Continuous intravenous calcium gluconate was administered to prevent citrate-induced hypocalcemia. Vital signs, electrocardiograms, and fluid balance were monitored continuously throughout the session. The leukocyte-rich concentrate collected was discarded and not reinfused. Exchange Transfusion (ET) procedure Exchange transfusion was performed via central venous access to ensure consistent flow. A cumulative volume equivalent to 1.0 to 2.2 times the infant’s estimated TBV was exchanged. The replacement fluid consisted of leukocyte-reduced packed red blood cells (O-negative or type-specific) reconstituted with fresh frozen plasma to achieve a target hematocrit of 40–50%. The exchange rate was controlled at 5–10 mL/kg/hr, strictly guided by real-time hemodynamic monitoring to prevent rapid fluctuations in blood pressure. The procedure aimed to reduce the WBC count, remove pertussis toxins, and correct coagulopathy and metabolic acidosis. Calcium gluconate was administered prophylactically to counteract potential hypocalcemia from citrate in the donor blood. Statistical analysis All statistical analyses were performed using R software (version 4.2.2). Given the limited sample size and non-normal distribution of the data, non-parametric methods were employed, with continuous variables expressed as medians with interquartile ranges (IQR). The Wilcoxon signed-rank test was utilized to evaluate within-group changes (pre- vs. post-treatment), whereas the Mann-Whitney U test was applied for between-group comparisons regarding reduction rates and baseline characteristics. Categorical variables, including mortality rates, were assessed using Fisher’ s exact test. Furthermore, to address clinical heterogeneity, an exploratory subgroup analysis was conducted by stratifying TL patients according to prior ET exposure (Primary TL vs. Salvage TL). All statistical tests were two-sided, and a p-value < 0.05 was considered statistically significant. Results Baseline characteristics We analyzed 14 patients with severe pertussis. To ensure transparency regarding treatment hierarchy and disease severity, patients were stratified into three distinct cohorts: Primary TL (TL alone, n = 4), ET Only (n = 4), and Salvage TL (TL after failed ET, n = 6). As shown in Table 1, the Salvage TL group represented a refractory population. These 6 patients were converted to TL due to insufficient leukoreduction (failure to lower WBC < 50 × 109/L) or persistent clinical deterioration despite undergoing prior ET sessions (range: 1–4 sessions). Patients in the TL groups underwent a median of 1 (range: 1–2) leukapheresis session. The median processed blood volume for TL procedures was maintained at 1.0 to 2.2 times the total blood volume (TBV) to ensure adequate leukoreduction. Table 1Baseline Characteristics and Treatment Outcomes of Pertussis PatientsVariablePrimary TL (n = 4)ET Only (n = 4)Salvage TL (n = 6)P-valueAge (months)25.5 (2.8–48.0)1.0 (1.0–1.5)2.5 (2.0–3.0)0.072Gender (Male/Female)2 / 23 / 13 / 31.000Weight (kg)8.5 (6.0–11.0)3.5 (2.7–4.7)6.0 (5.4–6.4)0.078Prior ET sessions001–4-Blood Product Usage - RBCs (Units/procedure)1.5 (1.5–1.5)2.75 (2.0–3.6)1.5 (1.5–1.5)0.020 - Plasma (mL/procedure)0 (0–0)200 (150–262)0 (0–0)0.020Outcomes WBC Reduction Rate (%)50.5 (41.9–58.5)39.6 (37.5–41.7)56.4 (55.0–59.8)0.200 Mortality, n (%)0 (0%)0 (0%)2 (33.3%)1.000Data are presented as median (interquartile range) or count (percentage). P-values were calculated comparing Primary TL vs. ET Only using the Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables. Patients in the Salvage group received 1 to 4 sessions of exchange transfusion prior to leukapheresis. RBCs in the TL group were utilized exclusively for extracorporeal circuit priming to prevent hemodilution, not for therapeutic exchange Baseline Characteristics and Treatment Outcomes of Pertussis Patients Data are presented as median (interquartile range) or count (percentage). P-values were calculated comparing Primary TL vs. ET Only using the Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables. Patients in the Salvage group received 1 to 4 sessions of exchange transfusion prior to leukapheresis. RBCs in the TL group were utilized exclusively for extracorporeal circuit priming to prevent hemodilution, not for therapeutic exchange Treatment efficacy and resource utilization primary TL vs. ET only In patients receiving single-modality therapy, Primary TL achieved a median WBC reduction of 50.5%, compared to 39.6% in the ET Only group. Importantly, the Primary TL group utilized significantly fewer blood resources (Median: 0 mL Plasma, 1.5 U RBCs for priming) compared to the ET group (Median: 200 mL Plasma, 2.75 U RBCs for exchange; p = 0.020), highlighting its feasibility in blood-shortage settings (Fig. 1). Salvage TL Efficacy: In the 6 refractory patients, TL sessions achieved a median WBC reduction of 56.4% (p = 0.031), effectively lowering the leukemic burden where prior ET had plateaued. Post-treatment platelet counts were comparable between the Primary TL and ET groups (p > 0.99). No significant difference in platelet reduction was observed, although this finding should be interpreted cautiously given the small sample size. Comparative Analysis of Hematological Parameters by Treatment Strategy. Individual patient trajectories (spaghetti plots) showing changes in (A) White Blood Cells, (B) Platelets, (C) Neutrophils, and (D) Lymphocytes before (Pre) and after (Post) treatment. Patients are stratified into three distinct groups: Primary TL (n = 4, red lines), ET Only (n = 4, blue lines), and Salvage TL (n = 6, green lines). Note that for groups with small sample sizes (Primary TL and ET Only, n = 4), the lowest achievable P-value for within-group reduction is 0.125. The Salvage TL group (n = 6) demonstrates statistically significant reductions (p < 0.05) despite being a refractory cohort Comparative efficacy: between-group analysis To evaluate the intrinsic efficacy of the two modalities, we first compared the Primary TL and ET Only groups. The median WBC reduction rate was numerically higher in the Primary TL group (50.5%, IQR: 41.9–58.5) compared to the ET Only group (39.6%, IQR: 37.5–41.7). However, possibly due to the limited sample size (n = 4 per group), this difference did not reach statistical significance (p = 0.200). In terms of platelet preservation, no statistically significant difference was observed in platelet reduction rates (p = 0.886) or post-treatment platelet counts between the Primary TL and ET Only groups (p > 0.99). These findings suggest that TL was not associated with a greater degree of thrombocytopenia in this limited cohort; however, the results should be interpreted cautiously given the small sample size. Notably, in the Salvage TL group (n = 6), which comprised patients with refractory hyperleukocytosis who had failed prior ET, TL achieved a substantial median WBC reduction of 56.4% (IQR: 55.0–59.8). This demonstrates that TL maintained high cytoreductive efficiency even in cases where ET had proven insufficient (Table 2). Table 2Key Laboratory Parameters Before and After TreatmentParameterPrimary TL (n = 4)ET Only (n = 4)Salvage TL (n = 6)WBC (×109/L) - Pre-treatment50.6 (48.3–56.7)43.0 (35.1–55.2)48.0 (44.7–55.7) - Post-treatment24.8 (19.7–33.1)25.6 (21.6–32.8)19.8 (19.4–24.4) - P-value0.1250.1250.031Neutrophils (×109/L) - Pre-treatment17.1 (16.0–18.4)25.7 (20.9–31.6)33.8 (24.9–39.8) - Post-treatment11.2 (9.7–12.5)12.6 (10.1–15.1)19.7 (17.1–29.0) - P-value0.1250.1250.031Lymphocytes (×109/L) - Pre-treatment31.1 (25.8–38.6)14.8 (10.9–20.2)10.8 (6.8–14.3) - Post-treatment12.4 (9.2–19.7)6.6 (6.1–6.9)5.0 (4.6–6.1) - P-value0.1250.1250.031Platelets (×109/L) - Pre-treatment447.5 (390.8–492.2)360.0 (304.5–485.5)434.0 (362.8–511.2) - Post-treatment158.5 (109.2–204.8)148.0 (114.2–204.8)114.0 (88.8–132.5) - P-value0.1250.1250.094Data are presented as median (interquartile range). Within-group comparisons (Pre vs. Post) were analyzed using the Wilcoxon signed-rank test. Due to the small sample size in Primary TL and ET groups (n = 4), the lowest achievable P-value is 0.125 (non-significant), despite the clear numerical reduction observed Key Laboratory Parameters Before and After Treatment Data are presented as median (interquartile range). Within-group comparisons (Pre vs. Post) were analyzed using the Wilcoxon signed-rank test. Due to the small sample size in Primary TL and ET groups (n = 4), the lowest achievable P-value is 0.125 (non-significant), despite the clear numerical reduction observed Safety and mortality outcomes Hemodynamic stability was maintained in all procedures, though systolic blood pressure exhibited greater variability in the TL sessions (range: 70–118 mmHg) compared to the relatively stable ET sessions (range: 97–114 mmHg). No procedures were aborted due to adverse events. Regarding survival outcomes, a distinct pattern emerged upon stratification. Mortality was 0% (0/4) in the Primary TL group and 0% (0/4) in the ET Only group. All deaths occurred exclusively in the Salvage TL group, where 2 of 6 patients (33.3%) succumbed to disease complications. Both fatal cases presented with extreme pre-procedure hyperleukocytosis (> 100 × 109/L) and persistent cardiorespiratory failure. These data strongly suggest that the mortality observed in the aggregate TL cohort was driven by the refractory severity of the disease in the Salvage group, rather than the procedure itself, confirming that Primary TL has a safety profile comparable to standard ET. Discussion This study evaluates the efficacy, safety, and feasibility of therapeutic leukapheresis (TL) versus exchange transfusion (ET) in managing severe pertussis-associated hyperleukocytosis in infants. Our findings highlight TL’s robust cytoreductive capacity and provide critical insights into risk stratification, particularly through the lens of our exploratory subgroup analysis. Comparative efficacy and mechanistic insights Our stratified analysis reveals nuanced insights into leukoreduction efficiency. In the Primary TL group, the median WBC reduction was numerically higher (50.5%) compared to the ET Only group (39.6%). Although this difference did not reach statistical significance (p = 0.200) likely due to the small sample size (n = 4), the trend favors TL. Importantly, in the Salvage TL group, TL achieved a 56.4% reduction even after ET had failed. This aligns with the mechanistic superiority of apheresis: unlike ET, which involves non-selective dilution, TL utilizes density-gradient centrifugation to specifically extract the pathological buffy coat [11, 12]. This specificity also confers a critical advantage in resource conservation. We found that ET required substantial donor blood volumes (median 2.75 U RBCs, 200 mL Plasma), whereas Primary TL consumed zero plasma and used minimal RBCs strictly for priming. This makes TL a crucial “blood-sparing” alternative in resource-limited settings. Regarding platelet preservation, we found no significant difference in post-treatment platelet counts between Primary TL and ET groups (p = 1.000). Both modalities resulted in transient thrombocytopenia, consistent with recent registry data [15]. However, platelets typically recovered without intervention, and the risk of severe bleeding remained low. Mortality and subgroup analysis A critical finding of this study is the nuance regarding mortality. Although the aggregate TL group had a 20% mortality rate, our stratified analysis provides a compelling explanation. Crucially, both deaths occurred exclusively in the “Salvage TL” subgroup (Mortality: 33.3%), whereas the “Primary TL” subgroup had a 0% mortality rate, identical to the ET Only group. Both fatal cases in the Salvage group presented with extreme baseline hyperleukocytosis (> 100 × 109/L) and had failed to respond to initial exchange therapies. This reflects the “malignant pertussis” phenotype, where refractory hyperleukocytosis and pulmonary hypertension are independent predictors of mortality [2]. Recent case reports emphasize that once this malignant phase is established, even aggressive interventions like ET may fail to reverse the course [16]. Our data suggest that the mortality in the TL group reflects the intractable severity of the disease in non-responders rather than procedural toxicity. In fact, studies from oncologic centers confirm that leukapheresis itself is a safe procedure even in high-risk patients, provided that fluid balance is strictly maintained [17]. Procedural challenges and hemodynamics The study cohort primarily consisted of infants under six months of age, whose physiological characteristic of low blood volume (median TBV: 0.5 L) makes them particularly susceptible to hemodynamic fluctuations. We observed that post-TL systolic blood pressure variability (70–118 mmHg) was more pronounced compared to post-ET (97–114 mmHg). This phenomenon may be directly related to differences in fluid management mechanisms between the two techniques. As mentioned in the Introduction, ET achieves blood volume replacement through isovolemic exchange. While removing pathological components, the exogenous plasma and red blood cells infused help maintain effective circulating volume, provide coagulation factors and buffering bases, thereby supporting a more stable hemodynamic state. In contrast, TL is a selective cytoreductive technology. Although the extracorporeal circuit is primed with blood to avoid hemodilution, there is no therapeutic fluid administration during the procedure, which may lead to a net reduction or redistribution of intravascular volume. Such subtle volume changes are amplified in infants with already low blood volume, manifesting as greater blood pressure variability [18]. Therefore, stricter real-time volume monitoring and hemodynamic management are essential during TL. This includes using infant-specific tubing to reduce extracorporeal circuit volume, precise adjustment of anticoagulant ratios, and prophylactic calcium supplementation to mitigate citrate-related risks [7, 19]. Additionally, some patients (particularly observed in the salvage therapy group) exhibited a leukocyte “rebound phenomenon” after cytoreduction, suggesting that repeated treatments or combined interventions may be necessary [9]. These findings highlight the importance of optimizing TL procedures in this special infant population. Clinical implications and risk stratification Based on our findings, we propose a stratified approach to managing severe pertussis. In settings of blood product shortages, TL represents a feasible first-line alternative to ET, as evidenced by our “Primary TL” group achieving 100% survival while significantly reducing donor blood usage. Conversely, for infants presenting with septic shock, ET remains a valuable modality for stabilizing hemodynamics and correcting acidosis [3, 8]. Furthermore, while TL can serve as a potent salvage therapy for patients with extreme hyperleukocytosis who fail initial ET, the high mortality observed in our “Salvage” subgroup (33%) suggests that future protocols should consider earlier integration with Extracorporeal Membrane Oxygenation (ECMO). Emerging evidence indicates that leukodepletion prior to or concurrent with ECMO may improve survival by reducing pulmonary vascular resistance [20]. Limitations and future directions Our study is subject to several limitations inherent to its retrospective design and small sample size (10 TL vs. 4 ET procedures), which restrict statistical power and the generalizability of our findings. First, selection bias is a significant confounder. The TL group exhibited substantial heterogeneity, with 60% (6/10) of patients having previously undergone failed ET sessions. These “Salvage TL” patients likely represented a cohort with more refractory disease and advanced physiological derangement compared to the “Primary TL” or ET-only groups, which may have skewed mortality outcomes against TL in the aggregate analysis. Second, the lack of randomization precludes definitive causal inferences regarding the comparative efficacy of one modality over the other. The choice of therapy was influenced by clinical judgment and blood product availability, introducing potential indication bias. Third, while we focused on short-term hematological and survival outcomes, long-term sequelae, such as neurodevelopmental outcomes following severe pertussis encephalopathy, were not captured. Finally, the use of non-parametric tests, while appropriate for our data distribution, may have limited the detection of subtle between-group differences. Future research should prioritize multi-center, prospective registries to accrue larger sample sizes, allowing for propensity score matching to balance baseline disease severity. Specifically, future protocols should rigorously distinguish between “Primary” and “Salvage” interventions to better define the optimal timing for leukapheresis. Investigating the role of TL as a bridge to ECMO in refractory cases also represents a critical area for future inquiry. Conclusion TL demonstrates robust leukoreduction efficiency (comparable to ET in primary cases and effective in refractory cases). Importantly, our data suggest that TL is safe as a first-line intervention, with the “Primary TL” subgroup achieving a 100% survival rate equivalent to ET. The mortality observed in the TL group was exclusively confined to refractory cases where TL was utilized as a salvage measure following ET failure. While ET remains a cornerstone for hemodynamically unstable infants requiring simultaneous correction of coagulopathy, TL emerges as a potent, blood-sparing alternative—particularly valuable in settings of blood product shortages or for patients with extreme hyperleukocytosis (> 50 × 109/L). We advocate for a risk-stratified approach: utilizing TL early for rapid cytoreduction in stable patients to conserve blood resources, while reserving ET for those in septic shock. Ultimately, the integration of TL into standardized treatment algorithms requires careful patient selection, stringent hemodynamic monitoring, and further validation through prospective controlled trials. Acknowledgements Not applicable. Abbreviations Therapeutic Leukapheresis Exchange Transfusion White Blood Cell (count) Platelet Pediatric Intensive Care Unit Neutrophil Lymphocytes Total Blood Volume Lactate Mononuclear Cell Anticoagulant Citrate Dextrose Solution A Authors’ contributions YXG (Yixin Gao) : Data collection, initial manuscript drafting. DL (Ding Liu): Major and critical revision of the manuscript. ZTL (Zitian Lu) & ZJC (Zhijiang Chen): Data validation and statistical analysis. GW (Gang Wang) & MHY (Minghui Yang): Interpretation of pathological data and patient follow-up. LYW (Linyan Wu) : Clinical supervision and critical revision of the manuscript. SWL (Shaowen Li): Case selection and conceptualization. YZP (Yongzheng Peng) & GQL (Guoqiang Liang) : Study supervision, academic guidance, and final approval of the manuscript. All authors have read and approved the final manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. All associated costs were supported by the personal resources of the Authors. Data availability The data used to support the findings of this study are available from the corresponding author upon request. Declarations Ethics approval and consent to participate This study is in accordance with the Declaration of Helsinki. The study was approved by the Medical Ethics Committee of the Zhujiang Hospital of Southern Medical University(2026-KY-041-01). The principle of informed consent was followed throughout the experiment, and information about the study was provided to their families. Written informed consent was obtained from the parents or legal guardians of all participants. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yixin Gao and Ding Liu contributed equally to this work and should be considered co-first authors. Yongzheng Peng and Guoqiang Liang contributed equally as co-corresponding authors. Contributor Information Yongzheng Peng, Email: tomgpt88@gmail.com. Guoqiang Liang, Email: LGQ11J@163.com. References Associated Data Data Availability Statement The data used to support the findings of this study are available from the corresponding author upon request.